Translational Research Program (TRP)

Translational Research Program (TRP) is sponsored by Blood Cancer United. Aims to accelerate the progression of promising scientific discoveries toward clinical application in blood cancers, including lymphoma.

###### About Blood Cancer United * DEI/Health equity commitment * Community Links Initiative * The Dare to Dream Project ###### Partners and suppliers Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a. m. –9 p.

m.

ET) * Explore all assistance programs * Co-Pay Assistance Program * Local Financial Assistance Program * Patient Travel Assistance Program * Pre-CAR T-cell Therapy Travel Assistance Program ###### Additional financial assistance * Medical Debt Case Management Program * Scholarships for Blood Cancer Survivors * Veterans Dental Partnership * Other financial assistance Talk to a Financial Assistance Intake Specialist(877) 557-2672(Monday–Friday 8:30 a.

m. to 5:00 p. m.

ET) ###### Policy and advocacy * What does the Office of Public Policy do? * Making treatment affordable for patients * Improving the quality of health insurance * Making clinical trials work for patients * Advocating for pediatric patients and survivors * Ensuring medicaid is available and stable * Accelerating progress in cancer R&D * Join the Mobile Action Network Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a. m.

–9 p. m. ET) * [](https://bloodcancerunited.

org/cart "Cart") * Blood cancers## Types of blood cancer ###### Leukemia Acute lymphoblastic leukemia (ALL)Acute myeloid leukemia (AML)Chronic lymphocytic leukemia (CLL)Chronic myeloid leukemia (CML)Hairy cell leukemia (HCL)Chronic myelomonocytic leukemia (CMML)Juvenile myelomonocytic leukemia (JMML)Large granular lymphocytic (LGL) leukemiaBlastic plasmacytoid dendritic cell neoplasm (BPDCN)B-cell prolymphocytic leukemia (B-PLL)T-cell prolymphocytic leukemia (T-PLL) ###### Lymphoma Non-Hodgkin lymphoma (NHL)Hodgkin lymphoma ###### Myeloma ###### Myelodysplastic syndromes (MDS) ###### Myeloproliferative neoplasms (MPNs) Essential thrombocythemia (ET)Myelofibrosis (MF)Polycythemia vera (PV) #### Blood cancer facts and statistics Leukemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS) are types of cancer that can affect the bone marrow, the blood cells, the lymph nodes, and other parts of the lymphatic system.

Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a. m. –9 p.

m.

ET) EmailLive Chat * Care and treatment## Navigate care by patient type ###### Adults Working with your care teamTreatment optionsKnow your rights, manage your financesManaging daily lifeAfter treatment ###### Young adults Working with your care teamTreatment optionsKnow your rights, manage your financesManaging daily lifeAfter treatment ###### Children and teens Working with your child's care teamCoping with a child's diagnosisKnow your rights, manage your financesCaring for your child during treatmentAfter treatment #### Cancer drug listing Find detailed information for nearly 200 cancer drugs, including brand and generic names for each drug, what it is intended to treat, how it is administered, and possible side effects.

Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a. m. –9 p.

m. ET) EmailLive Chat * Resources## Resources ###### Patient resources ###### Caregiver resources ###### Healthcare professional resources ###### Educational resources PublicationsWebcasts/VideosBlood cancer conferences3D Model LibraryPodcasts ###### Support resources Explore educational videos and webcasts covering emerging blood cancer therapies, survivorship, nutrition, caregiver tips, and much more.

Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a. m. –9 p.

m. ET) EmailLive Chat * Research## Research ###### Research Overview Research NewsWho we fundResearch we fundImpact on research progressResearch Grant Programs ###### Therapy Acceleration Program® (TAP) TAP portfolioProspective partners ###### Beat AML® Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a. m.

–9 p. m.

ET) EmailLive Chat * Get involved## Get involved ###### Fundraising Athletic EventsAmerica's Most Beautiful Bike RideBig ClimbClimb 2 CureDIY fundraiserFirefighter StairclimbLight The NightScenic Shore Bike TourShred for RedVisionaries of the YearStudent Visionaries of the YearVelo Palmetto ###### Ways to volunteer Volunteer Portal ###### Policy and advocacy ###### Corporate partnerships ###### College Campus Clubs Talk to an Information Specialist+1-800-955-4572(Monday–Friday 9 a.

m. –9 p. m.

ET) EmailLive Chat * Ways to give## Ways to give ###### Donate Donor-advised fundsHonor and memorial giftsMonthly givingCryptocurrencyStock giftsWills, annuities, and other planned giftsReal estate giftsWorkplace givingPayroll deductionsEmployee matching giftsVolunteer Grants ###### Charitable shopping Financial AssistanceLeukemiaSupportTreatmentsWays to Support Talk to Information Specialist +1-800-955-4572(Monday–Friday 9 a. m. –9 p.

m. ET) # Translational Research Program (TRP) [](https://bloodcancerunited. org/research/grants/translational-research-program-trp) ## The Translational Research Program (TRP) 2026-2027 cycle is now open The Translational Research Program (TRP) is designed to accelerate the progression of promising scientific discoveries toward clinical application in blood cancers.

The TRP supports projects with a clear path to clinical impact. Early-stage or discovery-focused research may be better suited for our Discovery Grant Program (DGP), and applicants with such projects are encouraged to apply through that mechanism.

### Application deadlines ### TRP Program Documents TRP Guidelines and Instructions (PDF) Policies and Procedures (PDF) TRP Funding Agreement Template (PDF) For the 2027 grant cycle, TRP applications must demonstrate translational readiness. The following criteria apply: * **Small molecule therapies:** Applications must include _in vivo_ proof of concept (POC) in appropriate animal models.

In select cases, strong _in vitro_ POC using patient-derived samples may be considered, depending on the mechanism of action. * **Cellular and immunotherapies:**_In vivo_ POC is strongly encouraged. However, _in vitro_ POC may be acceptable where it is most appropriate for the therapeutic approach.

Applications that do not meet these criteria should **not submit a Letter of Intent (LOI)**. ### Special opportunity for Australian grants The Snowdome Foundation is an Australian-based not-for-profit organization with whom Blood Cancer United is partnering to enhance our common goal to accelerate cures and better treatments for blood cancer patients.

Snowdome Foundation will contribute funding for one meritorious TRP application focused on blood cancer research from an investigator working in Australia, an Australian investigator working in another country, or to Australian and non-Australian researchers jointly applying as co-PIs. Applications must be submitted to the Blood Cancer United TRP program and will be evaluated within the general pool of TRP applications.

In addition, applications will be jointly reviewed by Blood Cancer United and Snowdome Foundation to ensure they meet the funding objectives of both organizations, and scientific progress of each awarded TRP will be evaluated by both organizations on an annual basis. Blood Cancer United will administer the grant program. ### Topics of interest include: * **Personalized medicine approach for cancer treatment.

** Advances in cancer care have significantly improved the lives of patients with hematologic diseases such as AML, CLL, Hodgkin and Non-Hodgkin Lymphomas, MM, and ALL. Blood Cancer United believes that, with time, cures can be achieved for certain diseases or subtypes of diseases. Therefore, Blood Cancer United will continue to support research that may revolutionize cancer care for any hematologic disease.

* **Development of novel therapies and/or novel therapeutic strategies** including those that target mutational and epigenetic events both in the tumor cells and within the microenvironment.

Such therapies can be applicable to any hematologic malignancies, but emphasis is warranted in the following areas: **a)** Aggressive subtypes of Non-Hodgkin Lymphoma including but not limited to DLBCL, tFL, MCL, PTCL, and ALCL **b)** Indolent lymphoma, including but not limited to: CLL, FL, WM (therapies with the potential to provide significant extension of lives of patients or total disease control in defined subtypes) **c)** Myeloid disorders including MPN/MDS/AML as well as lymphoid disorders such as ALL **d)** Multiple Myeloma and pre-emergent conditions * **Improvements in the safety and efficacy of stem cell transplantation.

** * **Blood Cancer United is especially interested in novel immunotherapy approaches and understanding novel immune synapses relevant to blood cancers. ** * **TRP is interested in focusing on diseases of high unmet need.

These can include aggressive diseases or diseases that lack effective therapy** * Budget submitted should reflect the actual needs of the project but cannot exceed $250,000 USD per year / $750,000 USD total for the three (3) years of the grant. * This budget ceiling includes all costs associated with the grant including indirect costs (often referred to as Institutional Overhead), which will be capped at 10% of the total award.

* Personnel Expenses: In total, no more than forty percent (40%) of the direct costs may be requested for the salary and fringe benefit expenses of professional staff with a postgraduate degree (i.e., MD, PhD, DVM) regardless of function or role.

This restriction does not apply to technical staff (lab assistants, nurses, etc.) _All applications must be submitted through the Blood Cancer United Research Portal (__https://bloodcancerunited. fluxx. io__).

_ **Should I start early? ** _Yes—applicants are strongly encouraged to begin well in advance of deadlines. _ _Yes.

You can save and return to your application at any time before submission. _ **Program Fit & Eligibility** **What research is a good fit? ** _Projects should be translational with clear potential for near-term clinical application.

_ **What is not a good fit? ** _Early-stage or discovery research is typically not competitive and should be directed to the Discovery Grant Program. _ **Are there proof-of-concept requirements?

** _Yes—applications must include appropriate in vivo or in vitro proof of concept depending on the approach. _ _Independent investigators (PhD, MD, DVM, or equivalent) at non-profit institutions worldwide. _ _Predoctoral and postdoctoral researchers are not eligible.

_ **What are the application phases? ** 1. _Letter of Intent (LOI)_ 2.

_Full Application (by invitation only)_ **What happens after I submit an LOI? ** _You will be notified if you are invited to submit a full application. _ **Can I make changes after submitting?

** _Changes require prior approval and may not be permitted. _ **How much funding can I request? ** _Up to $250,000 per year for up to 3 years (maximum $750,000 total).

_ **Are indirect costs allowed? ** _Yes, up to 10% of the total award. _ **Is there a cap on salaries?

** _Yes—no more than 40% of direct costs can be used for professional staff salaries. _ **Formatting & Submission** **What formatting rules apply? ** * _Preset margins and spacing must not be altered_ * _Character limits are strictly enforced_ **What happens if I don’t follow the rules?

** _Your application may be administratively disqualified. _ **Can I submit additional materials? ** _No—only requested documents should be included.

_ **Can I include a Co-PI? ** _Yes (up to two), and a Co-PI may be required if the PI does not have a strong record of hematological research. _ **Can I change my team after the LOI?

** _Changes require approval and are not guaranteed. _ **Can I apply to multiple programs? ** _Yes, as long as the research aims do not overlap.

_ **How are applications evaluated? ** _Applications are reviewed based on:_ * _Scientific merit and innovation_ * _Feasibility and resources_ * _Investigator qualifications_ **Will I receive reviewer feedback? ** _Feedback is only provided for applications reviewed by the full committee.

_ **What can lead to disqualification? ** * _Missing required sections_ * _Ignoring formatting rules_ * _Including unrequested materials_ **Important Notice**: The information provided in this FAQ is a summary for convenience only and is not exhaustive. Applicants must review the complete official Guidelines and Instructions to ensure full compliance and understanding of all procedures.

**If your question is not addressed here, please contact:** **researchprograms@bloodcancerunited. org** #### **See our active TRP grantee portfolio** Refer to the program guidelines and instructions in the _program_ section above or emailresearchprograms@bloodcancerunited. org.

I was funded by the Blood Cancer United TRP in 2008 and 2025 for antibody-targeted therapeutics for lymphoma and the development of novel CRISPR-modified CAR T cells. These funds have been instrumental and transformative in advancing novel treatments for lymphoma and other blood cancers. Blood Cancer United’s investment in high-impact science and investigators is especially critical now, amid reduced research funding nationwide.

University of California at Davis Translational Research Program Gene-edited CD19 CAR-T cells with superior proliferation, persistence and serial-killing activity "A few years ago, we discovered that a drug that was previously given to patients with Parkinson and Alzheimer's disease can actually help patients with refractory leukemia and lymphoma. In the meantime, our lab uncovered the basic mechanism of how this drug works.

I am grateful for the support from Blood Cancer United, which now gives us the rare opportunity to repurpose this drug to benefit patients with refractory blood cancers. " Translational Research Program Rational repurposing effort to disrupt beta-catenin protein degradation in B-cell malignancies The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.

### Get connected, stay informed ### Call an Information Specialist Highly trained oncology social workers and nurses. (Monday–Friday 9 a. m.

–9 p. m. ET) Your donation supports groundbreaking research and vital patient services.

(Monday–Friday 9:30 a. m. –5:00 p.

m. ET) * Financial transparency and independence * _*Bilingual content/Contenido bilingüe_ * [](https://www. facebook.

com/BloodCancerUnited) * [](https://instagram. com/bloodcancerunited/) * [](https://x. com/BloodCancerUtd) * [](https://www.

linkedin. com/company/bloodcancerunited) * [](https://www. tiktok.

com/@bloodcancerunited) * [](https://www. youtube. com/@BloodCancerUnited) * [](https://www.

threads. com/@bloodcancerunited) * [](https://bloodcancerunited. org/blog) The Blood Cancer United mission: Cure blood cancer and improve the quality of life of all patients and their families.

Blood Cancer United funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. Blood Cancer United is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your financial advisor if you have more questions.

Tax Identification Number: 13-5644916